Amgen Inc (AMGN)
NASDAQ:AMGN
Want to see AMGN full AI Analyst Report?
AMGN Stock Chart & Stats
$348.22
-$0.21(-0.08%)
At close: 4:00 PM EST
$348.22
-$0.21(-0.08%)
Day’s Range― - ―
52-Week Range$261.43 - $391.29
Previous CloseN/A
Volume614.18K
Average Volume (3M)2.54M
Market Cap
$187.71B
Enterprise Value$233.19B
Total Cash (Recent Filing)$9.13B
Total Debt (Recent Filing)$54.60B
Price to Earnings (P/E)22.8
Beta0.39
Next Earnings
Apr 30, 2026EPS Estimate
4.82Next Dividend Ex-DateN/A
Dividend Yield3%
Share Statistics
EPS (TTM)5.29
Shares Outstanding539,067,700
10 Day Avg. Volume2,215,721
30 Day Avg. Volume2,537,048
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)20.34
Price to Sales (P/S)4.79
P/FCF Ratio21.74
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue6.34
Enterprise Value/Gross Profit9.00
Enterprise Value/Ebitda12.48
Forecast
1Y Price Target
$369.00Price Target Upside5.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering23
EPS Forecast (FY)22.39
Revenue Forecast (FY)$37.85B
Bulls Say, Bears Say
Bulls Say
AI Partnership And Data AdvantagePartnership with Nvidia and access to deCODE's large human dataset enable building advanced AI models to speed discovery and development, potentially increasing the pipeline's productivity and long-term value.
Diversified Commercial MomentumStrong sales across multiple products including Repatha, Uplizna, and Imdelltra, supported by durable volume growth and broad formulary access, provide diversified revenue drivers that can sustain top-line momentum despite pricing pressures.
Subcutaneous Tepezza DeliveryLate-stage results for subcutaneous Tepezza delivered via an on-body injector, combined with manufacturing efficiency gains at a new plant, could broaden patient access by reducing dependence on infusion centers and support franchise growth in thyroid eye disease.
Bears Say
Administration Uncertainty And Home-use CompetitionClinical materials indicating clinician or trained-designee administration, plus a competitor offering a true home-use autoinjector, create uncertainty about patient adoption of the on-body injector and could erode Tepezza's convenience advantage.
MariTide Efficacy, Tolerability And Competitive RiskUncertainty about MariTide's efficacy and tolerability, including nausea and vomiting concerns, combined with intensifying competition from long-acting weight-loss therapies, may limit the drug's market upside.
Reimbursement And Exclusivity HeadwindsProjected revenue erosion from biosimilars and loss of exclusivity for key drugs, together with Medicare Part D redesign and a higher contract mix for some products, could create meaningful pressure on future sales unless offset by new launches.
Amgen News
AMGN FAQ
What was Amgen Inc’s price range in the past 12 months?
Amgen Inc lowest stock price was $261.43 and its highest was $391.29 in the past 12 months.
What is Amgen Inc’s market cap?
Amgen Inc’s market cap is $187.71B.
When is Amgen Inc’s upcoming earnings report date?
Amgen Inc’s upcoming earnings report date is Apr 30, 2026 which is in 14 days.
How were Amgen Inc’s earnings last quarter?
Amgen Inc released its earnings results on Feb 03, 2026. The company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.734 by $0.556.
Is Amgen Inc overvalued?
According to Wall Street analysts Amgen Inc’s price is currently Undervalued.
Does Amgen Inc pay dividends?
Amgen Inc pays a Quarterly dividend of $2.38 which represents an annual dividend yield of 3%. See more information on Amgen Inc dividends here
What is Amgen Inc’s EPS estimate?
Amgen Inc’s EPS estimate is 4.82.
How many shares outstanding does Amgen Inc have?
Amgen Inc has 539,067,700 shares outstanding.
What happened to Amgen Inc’s price movement after its last earnings report?
Amgen Inc reported an EPS of $5.29 in its last earnings report, beating expectations of $4.734. Following the earnings report the stock price went up 8.154%.
Which hedge fund is a major shareholder of Amgen Inc?
Currently, no hedge funds are holding shares in AMGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Amgen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$369.00 (5.97% Upside)
$369.00 (5.97% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 653.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Bullish
Bullish news 79%
Bearish news 29%
Bearish news 29%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.62%
12-Months-Change
Fundamentals
Return on Equity
96.65%
Trailing 12-Months
Asset Growth
-1.36%
Trailing 12-Months
Company Description
Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
AMGN Company Deck
AMGN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized broad, multi-product commercial momentum, strong financial performance, substantial R&D investment, and encouraging late-stage pipeline progress (notably Repatha, Meritide, biosimilars, rare disease approvals, and Imdeltra). Key challenges include a significant regulatory action on Tavneos, slower-than-expected event accrual for the olpasiran outcome study, several program deprioritizations, and anticipated near-term sales pressure from biosimilars/generics and seasonal/inventory headwinds. On balance, the positives — sustained growth across multiple franchises, clear 2026 guidance range, and a deep late-stage pipeline — outweigh the notable but addressable setbacks.View all AMGN earnings summariesAMGN Revenue Breakdown
13.09% Prolia
9.92% Enbrel
6.66% XGEVA
6.65% Repatha
63.69% Other
AMGN Stock 12 Month Forecast
Average Price Target
$369.00
▲(5.97% Upside)
Technical Analysis
Ownership Overview
0.20% Insiders
24.79% Mutual Funds
0.51% Other Institutional Investors
44.78% Public Companies and Individual Investors